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Abstract: Background: The HIV drugs lopinavir and ritonavir have recently been reported to cause
transient adrenal insufficiency in preterm newborns. We, therefore, considered HIV drugs as a cause of
transiently elevated 17-hydroxyprogesterone (17OHP) levels in a neonatal screening test for congenital
adrenal hyperplasia in a preterm girl exposed to zidovudine, efavirenz, tenofovir, and emtricitabine.
Objective: So far, HIV drugs have not been tested for their effect on steroidogenesis and the steroidogenic
enzyme activity of CYP21A2 specifically in an in vitro system. Methods: We tested the effect of efavirenz,
tenofovir, emtricitabine, and zidovudine on steroidogenesis of human adrenal H295R cells. Cells were
treated with the drugs at different concentrations including concentrations in therapeutic use. The effect
on CYP21A2 activity was assessed by testing the conversion of radiolabeled 17OHP to 11-deoxycortisol.
Cell viability was tested by an MTT assay. In addition, recombinant human CYP21A2 protein was used to
assess direct drug effects on CYP21A2 activity. Results: We observed significantly decreased CYP21A2
activity in both in vitro testing systems after treatment with efavirenz at therapeutic concentrations.
Moreover, efavirenz affected cell viability. By contrast, the other test drugs did not affect steroidogenesis.
Follow-up of our patient revealed elevated 17OHP and androgen levels during the first weeks of life, but
values normalized spontaneously. Genetic testing for CYP21A2 mutations was negative. Thus, it remains
unsettled whether the transient 17OHP elevation in this baby was due to a drug effect. Conclusion: The
HIV drug efavirenz inhibits CYP21A2 activity in vitro through direct interaction with enzyme catalysis
at therapeutic concentrations. This may have clinical implications for HIV treatment in children and
adults. However, so far, clinical data are scarce, and further studies are needed to be able to draw clinical
conclusions.
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Abstract
Background: The HIV drugs lopinavir and ritonavir have re-
cently been reported to cause transient adrenal insufficiency in 
preterm newborns. We, therefore, considered HIV drugs as a 
cause of transiently elevated 17-hydroxyprogesterone (17OHP) 
levels in a neonatal screening test for congenital adrenal hyper-
plasia in a preterm girl exposed to zidovudine, efavirenz, teno-
fovir, and emtricitabine. Objective: So far, HIV drugs have not 
been tested for their effect on steroidogenesis and the ste-
roidogenic enzyme activity of CYP21A2 specifically in an in vi-
tro system. Methods: We tested the effect of efavirenz, tenofo-
vir, emtricitabine, and zidovudine on steroidogenesis of hu-
man adrenal H295R cells. Cells were treated with the drugs at 
different concentrations including concentrations in therapeu-
tic use. The effect on CYP21A2 activity was assessed by testing 
the conversion of radiolabeled 17OHP to 11-deoxycortisol. Cell 
viability was tested by an MTT assay. In addition, recombinant 
human CYP21A2 protein was used to assess direct drug effects 
on CYP21A2 activity. Results: We observed significantly de-
creased CYP21A2 activity in both in vitro testing systems after 
treatment with efavirenz at therapeutic concentrations. More-
over, efavirenz affected cell viability. By contrast, the other test 
drugs did not affect steroidogenesis. Follow-up of our patient 
revealed elevated 17OHP and androgen levels during the first 
weeks of life, but values normalized spontaneously. Genetic 
testing for CYP21A2 mutations was negative. Thus, it remains 
unsettled whether the transient 17OHP elevation in this baby 
was due to a drug effect. Conclusion: The HIV drug efavirenz 
inhibits CYP21A2 activity in vitro through direct interaction 
with enzyme catalysis at therapeutic concentrations. This may 
have clinical implications for HIV treatment in children and 
adults. However, so far, clinical data are scarce, and further 
studies are needed to be able to draw clinical conclusions.
© 2019 S. Karger AG, Basel
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Introduction
Adrenal insufficiency (AI) may be a life-threatening 
condition due to inadequate production of glucocorti-
coids and mineralocorticoids. It is classified as primary 
AI (underlying cause in the adrenals) and as secondary AI 
(underlying defect in the hypothalamic-pituitary control 
of the adrenals). In newborns, congenital adrenal hyper-
plasia (CAH) due to genetic mutations in the CYP21A2 
gene is the leading cause of primary AI and affects about 
1 in 10,000–15,000 newborns in Europe [1–3]. CYP21A2 
is essential for both mineralocorticoid and glucocorticoid 
production because it mediates the 21-hydroxylation of 
progesterone to deoxycorticosterone and 17-hydroxy-
progesterone (17OHP) to 11-deoxycortisol (11DOC) [2]. 
The severe, classic, salt-wasting form of CYP21A2 defi-
ciency is a potentially life-threatening condition charac-
terized by low or absent production of cortisol and aldo-
sterone as well as overproduction of adrenal androgens, 
and manifests early in life [1–4]. The milder, non-classic 
form of CAH may manifest later in life, and predomi-
nantly results in adrenal androgen excess. While girls 
with classic CAH often present ambiguous genitalia at 
birth due to intrauterine overproduction of androgens 
[5], boys do not show physical signs suggestive of CAH 
[4, 6]. Therefore, many countries have introduced a neo-
natal screening program for early diagnosis of CAH based 
on blood 17OHP levels reflecting CYP21A2 enzyme de-
ficiency [3, 6].
However, 17OHP blood screening by heel stick may 
reveal both false-positive and false-negative results. The 
interpretation of elevated levels in preterm [7] or stressed 
newborns [8] is especially challenging. Also, 17OHP may 
be elevated in other rare forms of CAH, such as HSD3B2, 
CYP11B2, or P450 oxidoreductase deficiencies, which 
also require prompt corticosteroid replacement therapy 
[9, 10]. Furthermore, the activities of adrenal enzymes 
can be influenced by drugs and toxins and thereby 
cause primary AI in rare cases. Drugs such as ketocona-
zole, metyrapone, etomidate, mitotane, and abiraterone 
are known inhibitors of steroid enzymes, including 
 CYP11A1, CYP17A1, CYP21A2, and CYP11B1/2 
[11, 12].
In recent clinical studies, it has been suggested that 
some HIV drugs may also affect steroidogenesis. Elevated 
serum 17OHP and dehydroepiandrosterone levels were 
found in neonates treated perinatally with the HIV-1 pro-
tease inhibitors lopinavir and ritonavir [13, 14]. Three 
premature babies presented with clinical and biochemical 
signs of adrenal dysfunction after postnatal treatment 
with these drugs [13], while a full-term neonate was not-
ed to have high serum 17OHP and potassium levels after 
pre- and postnatal treatment with lopinavir and ritonavir 
[14]. In our clinic, we also followed a preterm baby of an 
HIV-infected mother for repeatedly high levels of 17OHP 
during neonatal screening. The drugs efavirenz, emtri-
citabine, and tenofovir (Atripla®) were prescribed to the 
mother during pregnancy to reduce the mother-to-child 
transmission of HIV, and the neonate was treated pro-
phylactically with zidovudine postnatally. According to 
the current literature, these HIV drugs have not been 
 tested for a possible effect on steroidogenesis.
In 2017, the World Health Organization reported that 
about 18 million women worldwide were infected with 
HIV. They also reported that HIV treatment during preg-
nancy was very effective and reduced the mother-to-child 
transmission of an HIV infection from 45 to 2% [15]. 
However, this means that a significant number of neo-
nates are exposed to HIV drugs very early in life, and pos-
sible adverse effects of the drugs might be of significance.
Therefore, motivated by the clinical observations and 
stimulated by the fact that none of the HIV drugs in rou-
tine use has been tested for an effect on adrenal steroido-
genesis, we tested some of these drugs for their effect on 




A 46,XX baby girl was born at 26 weeks of gestation after pre-
mature rupture of membranes to an HIV-infected mother. Birth 
weight was 760 g (P 25–50) and length 35 cm (P 50–75). Because 
of premature contractions, the mother received 2 doses of beta-
methasone at 23 5/7 weeks of gestation for induction of lung mat-
uration. In addition, the mother was treated with the HIV drugs 
tenofovir, efavirenz, and emtricitabine (Atripla®) throughout 
pregnancy. The newborn was then treated with zidovudine for 
(post)exposure prophylaxis during the first 4 weeks of life (Fig. 1). 
The girl showed a normal physical exam at birth, including normal 
female external genitalia without signs of virilization, but she re-
ceived a single dose of hydrocortisone (0.1 mg/kg) for low blood 
pressure. Initial laboratory workup revealed normoglycemia and 
normal electrolyte and 17OHP (80 nM; reference value for the ges-
tational and postnatal age < 192 nM) serum levels. However, while 
glucose and electrolyte levels remained normal, 17OHP increased 
to 292 nM on day 15 (normal level for gestational and postnatal age 
< 141 nM) and was still elevated on day 19 (132 nM; normal < 104 
nM; DELFIA Neonatal 17αOH-progesterone kit, PerkinElmer, 
Switzerland), which prompted further workup for possible CAH. 
ACTH (8.3 ng/L; reference range 7.2–63.3) and cortisol (396 nM; 
reference range 171–536 nM) were both within the normal range 
at 3 weeks of age. Urine steroid profiling (gas chromatography-
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gesterone and androgen metabolites (online suppl. Table 1; see 
www.karger.com/doi/10.1159/000500522 for all online suppl. 
 material). Finally, serum 17OHP normalized after 4 weeks (Fig. 1), 
and the clinical course was completely unremarkable. The baby 
was discharged home at 36 1/7 weeks postconceptional age. She is 
currently 3 years old and healthy.
Urinary Steroid Profiling
Urinary steroid profiling was performed by an established, val-
idated in-house method (gas chromatography-mass spectrome-
try) [16–19]. Measurements of spot urines (collected from cotton 
balls inserted in diapers) were normalized to creatinine (Quanti-
Chrom Creatinine Assay; DICT-500, BioAssay Systems, Hayward, 
CA, USA). Accordingly, results are expressed in micrograms per 
millimole creatinine (online suppl. Table 1) as previously de-
scribed for healthy neonates during the first year of life [16–18].
Genetic Analysis of the CYP21A2 Gene
Three fragments of the CYP21A2 gene were amplified by PCR 
from genomic DNA using the CAH StripAssay® (ViennaLab Di-
agnostics, Vienna, Austria). In addition, all coding sequences of 
the CYP21A2 gene were sequenced with the Sanger method using 
internal sequencing primers. For analysis, the CYP21A2 reference 
sequence NM_000500.6 was used.
In vitro Cell Assays
The antiretroviral HIV drugs zidovudine (3′-azido-3′deoxy-
thymidine) and efavirenz were purchased from Sigma-Aldrich 
(Buchs, Switzerland), and tenofovir and emtricitabine from To-
ronto Research Chemicals (Toronto, ON, Canada). Radiolabeled 
[3H]-17OHP (50 Ci/mmol) was from American Radiolabel Chem-
icals Inc. (St. Louis, MO, USA). MTT (3-[4,5-dimethylthiazol-
2-yl]-2,5-diphenyltetrazolium bromide) was obtained from Sig-
ma-Aldrich (Buchs, Switzerland). The human adrenal carcinoma 
cell line NCI-H295R originates from American Type Culture Col-
lection.
NCI-H295R cells were cultured under standard conditions [12, 
20]. Test drugs were dissolved in dimethyl sulfoxide (DMSO); final 
concentrations used for treatment were within and above the 
range of mean effective serum concentrations reported in use for 
HIV therapy. Cells were grown in 12-well plates. Drugs were add-
ed to normal growth medium for 3 and 24 h. Control cells were 
treated with 0.1% (v/v) DMSO. Radiolabeled [3H]-17OHP (50,000 
cpm/well) was added to the culture medium for the last 90 min of 
incubation. Steroids were then extracted from cell supernatants 
and separated by thin-layer chromatography as described [21]. 
Steroids were visualized on a Fuji PhosphoImager FLA-7000 (Fuji-
film, Dielsdorf, Germany) and densitometrically quantified using 
Multi Gauge software (Fujifilm). The conversion (in %) of 17OHP 
to 11-deoxycortisol was taken as a measure of CYP21A2 activity.
The MTT cell proliferation assay was used to determine cell vi-
ability and proliferation of NCI-H295R cells treated with HIV 
drugs. In brief, cells were cultured on 96-well plates at a density of 
15,000 cells/well in 200 µL medium. After 48 h, cells were treated 
with the HIV drugs for 3 and 24 h, and cell proliferation was as-
sessed by adding 20 µL of MTT to the culture medium for 3 h be-
fore reading the absorbance at 540 nm on a Spectramax M2e mi-
croplate reader (Molecular Devices, CA, USA). In this assay, the 
absorbance at 540 nm correlates directly to the number of viable 
cells.
In vitro Studies with Recombinant CYP21A2 Protein
Human CYP21A2 protein was expressed in Escherichia coli 
strain C43 (DE3) (Lucigen, Middleton, MI, USA) and purified via 
metal chelate (IMAC) and ion exchange chromatography as de-
scribed [22]. Carbon monoxide difference spectroscopy was car-
ried out for quantitative enzyme characterization following the 
typical absorption maximum at 450 nm with an extinction coef-
ficient of 91 mM–1 × cm–1. Human NADPH-cytochrome P450 re-
ductase (POR) was expressed in E. coli C43 (DE3) and purified by 
IMAC as described [23].
Inhibition studies were performed in reconstituted in vitro as-
says in 50 mM HEPES buffer (pH 7.4) containing 20% glycerol and 
100 µM 1,2-dilauroyl-sn-glycerol-3-phosphocholine. Before use, 
the buffer was sonicated in a water bath for 5 min for the reconstitu-
tion of 1,2-dilauroyl-sn-glycero-3-phosphocholine vesicles. The fi-
nal concentration of human CYP21A2 was 0.1 µM, and equal 
amounts of human POR were added. Additionally, the reaction con-
tained an NADPH regeneration system consisting of 5 mM glucose-
6-phosphate, 1 mM MgCl2, and glucose-6-phosphate dehydroge-
nase. The steroid substrate 17OHP was added at a concentration of 
5 µM, and the drugs were tested at concentrations of 5 or 50 µM. The 
substrate concentrations were kept below saturation but in excess of 
the Km for CYP21A2. The final DMSO concentration was kept < 2%. 
The reaction was started with 5 mM NADPH and incubated in a 
shaking water bath for 4–7 min at 37  ° C. The reaction was quenched 
with chloroform. Steroids were extracted twice with chloroform, 
dried, and stored at –20  ° C for HPLC analysis, specifically the mea-





























Fig. 1. Transiently elevated serum 17-hydroxyprogesterone 
(17OHP) levels in a newborn under the influence of Atripla® (efa-
virenz, tenofovir, and emtricitabine) prenatally and Retrovir® (zi-
dovudine) during 4 weeks postnatally. Note that the newborn re-
ceived 1 dose of hydrocortisone in the first 24 h after birth. Peak 
17OHP levels were seen on day 15 and normalized by day 28 ac-
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Steroid analysis was finally carried out by reverse phase (RP)-
HPLC using a Jasco RP-HPLC system of the LC900 series (Jasco 
Inc, Easton, MD, USA) and a 4.6 × 125 mm NucleoDur C18 Isis 
RP column (Macherey-Nagel, Düren, Germany). Samples were 
measured within 30 min at 240 nm and a flow rate of 0.8 mL/min; 
solvent gradient was as follows: 80% solvent A (10% acetonitrile in 
water) for 13 min, 60% solvent A for 7 min, 80% solvent B (100% 
acetonitrile) for 2 min, and 80% solvent A for 8 min.
In silico Protein Structure Analysis
A 3D crystal structure of human CYP21A2 was obtained from 
the Protein Data Bank (PDB; www.rcsb.org) for docking analysis 
of efavirenz binding [24]. However, the structure (PDB #4Y8W) 
has multiple residues missing that creates gaps in the peptide back-
bone making it unstable during molecular-dynamic analysis. A 
model building using sequence conservation information and sec-
ondary structure analysis was needed to fill the gaps and create a 
complete structure suitable for docking and molecular-dynamic 
calculations. To get the secondary structure information of miss-
ing residues, we performed sequence alignments with multiple 
CYP21A2 protein sequences from different organisms (online 
suppl. Fig. 1) and made in silico calculations with the programs 
YASARA [25] and WHATIF [26]. Missing hydrogen atoms were 
added with YASARA [25], which was also used for all subsequent 
computations unless stated otherwise. Afterwards, the system was 
subjected to 500 ps explicit solvent MD simulations at 310 K, pre-
ceded by 500 steps of steepest descent and simulated annealing 
minimization with the AMBER15 force field and the TIP3P water 
model [27, 28]. All subsequent MD simulations retained these set-
tings. The resulting minimum energy structure was used with 
AutoDock Vina [29] for docking experiments with efavirenz. Or-
thorhombic docking was grid established around the central heme. 
The final poses were selected based on their docking scores and 
resemblance to the cocrystallized progesterone in the template 
structure (PDB: 4Y8W). Structure models were depicted with Py-
MOL (www.pymol.org) and rendered as ray-traced images with 
POV-Ray (www.povray.org). Ligand interactions were analyzed 
and depicted with LigPlot+ (http://www.ebi.ac.uk/thornton-srv/
software/LigPlus/).
Statistical Analysis
Statistical analysis was performed with Microsoft Excel and 
Prism 6 software (Graph Pad Software Inc., San Diego, CA, USA). 
Student’s t test was used to evaluate significant differences between 
values. Quantitative data represent the mean of 2 or 3 independent 
experiments; error bars indicate SEM. Significance was set at val-
ues of p < 0.05 (* p < 0.05, ** p < 0.01 and *** p < 0.001).
Results
Biochemical data of neonates exposed to the HIV 
drugs lopinavir and ritonavir suggested an inhibitory 
 effect on adrenal steroidogenesis [13, 14]. Similarly, 
we observed elevated serum 17OHP levels and urinary 
steroid profile abnormalities consistent with diminished 
CYP21A2 activity and maybe diminished CYP17A1 ac-
tivity in a preterm girl after exposure to tenofovir, efavi-
renz, and emtricitabine in utero, and zidovudine postna-
tally (see Case Report; Fig. 1 and online suppl. Table 1). 
Genetic testing excluded mutations in the CYP21A2 gene.
Efavirenz Inhibits CYP21A2 Activity
The effect of the antiviral HIV drugs zidovudine, em-
tricitabine, tenofovir, and efavirenz on steroidogenesis 
was tested in the adrenal H295R cell line. Efavirenz is a 
nonnucleoside reverse transcriptase inhibitor. Its report-
ed mean effective serum concentration is 1.6–9.1 μM 
(https://www.medicines.org.uk/emc/product/8659/
smpc). The drug was tested at 4 concentrations (1, 5, 10, 
and 50 μM) after 3 and 24 h of incubation. A significant 
decrease in CYP21A2 activity was observed after 3-h in-
cubation starting at 5 μM (p < 0.05), with a clear addition-
al dose effect at higher concentrations (10 and 50 μM; 
p < 0.01, p < 0.001) (Fig. 2a). By contrast, after 24-h incu-
bation, CYP21A2 inhibition was only observed at the 
highest (50 μM) efavirenz concentration (p < 0.001) sug-
gesting that longer incubation may allow the cells to com-
pensate for the drug effect to some degree (Fig. 2b).
Zidovudine and emtricitabine are nucleoside reverse 
transcriptase inhibitors. Reported mean effective serum 
concentrations for zidovudine are 4.45–8.5 μM (https://
www.medicines.org.uk/emc/product/6811/smpc) and for 
emtricitabine 4.5–10 μM (https://www.medicines.org.uk/
emc/product/18/smpc). H295R cells were treated with 
 zidovudine and emtricitabine at 2 concentrations (10 and 
50 µM) for 3 and 24 h. Both drugs showed no effect on 
CYP21A2 activity at either timing (Fig. 2). Tenofovir is 
also a nucleoside reverse transcriptase inhibitor, but in 
contrast to zidovudine and emtricitabine its mean 
 effective serum concentration is markedly lower (0.74–
1.13 µM) (https://www.medicines.org.uk/emc/product/ 
771/smpc). Therefore, tenofovir was tested at lower con-
centrations (1 and 5 µM) for 3 and 24 h. No effect on 
CYP21A2 activity was observed (Fig. 2).
As the HIV drugs efavirenz, tenofovir, and emtrici-
tabine are often in use as triple medication (Atripla®), we 
also tested the 3 compounds together in our H295R cell 
system. These experiments revealed the same inhibitory 
effect on CYP21A2 as observed with efavirenz alone 
(Fig. 2, bottom).
Furthermore, to assess whether the tested drugs may 
affect H295R cell viability, we performed an MTT cell 
proliferation assay. Efavirenz starting at 5 µM reduced cell 
proliferation significantly compared to control cells (on-
line suppl. Fig. 2). Efavirenz at 10 and 50 µM seemed ex-
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H295R cells treated with the Atripla® combination, while 
no effect was seen with single treatments of zidovudine, 
emtricitabine, and tenofovir.
Efavirenz Is a Direct Inhibitor of CYP21A2 Activity
We also tested the direct effect of the 4 HIV drugs on 
enzyme catalysis using human recombinant CYP21A2 
protein and 17OHP as substrate. Similar to the cell cul-
ture experiments, we found that efavirenz inhibited 
 CYP21A2 activity to a significant degree, decreasing the 
product formation to 30% at a concentration of 50 µM 
efavirenz (Fig. 3). By contrast, no effect on enzyme activ-
ity was found for the 3 other test drugs (Fig. 3).
Computational Docking of Efavirenz into the Human 
CYP21A2 Crystal Structure
Efavirenz was docked into the crystal structure of hu-
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Fig. 2. Efavirenz (EFV) inhibits CYP21A2 
activity at therapeutic concentrations, 
while no effect was seen for the other tested 
HIV drug compounds. Human adrenal 
NCI-H295R cells were treated with EFV, 
emtricitabine (FTC), tenofovir (TDF), and 
zidovudine (AZV) at various concentra-
tions for 3 h (a) and 24 h (b) to test for their 
effect on steroidogenesis. Steroids were ex-
tracted from cell supernatants and separat-
ed by thin-layer chromatography. Relative 
CYP21A2 activity was calculated by as-
sessing the conversion of 17-hydroxy-
progesterone (17OHP) to 11-deoxycortisol 
(11DOC). Data are means ± SEM of 2–4 
independent experiments. * p < 0.05, ** p < 
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position of CYP21A2 structures with either progesterone 
or efavirenz docked into the active site revealed similarities 
in binding poses (Fig. 4b, c). We observed a distance of 
2.8 Å between efavirenz and heme iron at the active site of 
CYP21A2 (Fig. 4a). Efavirenz is smaller than the proges-
terone molecule and may achieve several potential binding 
poses inside CYP21A2. However, the occupation of the 
CYP21A2 catalytic site by efavirenz would inhibit the 
binding and metabolism of CYP21A2 steroid substrates. A 
comparison of CYP21A2 and CYP17A1 crystal structures 
complexed with steroid substrates and docked efavirenz 
into the crystal structure of CYP21A2 revealed similarities 
in interacting residues; the distance of the efavirenz nitro-
gen to the central heme iron of CYP21A2 was in similar 
range (Fig. 4a). Binding of efavirenz with CYP21A2 shares 
many similarities with natural substrates of CYP21A2 with 
identical active site residues such as Ser109, Gly292, and 
Leu364 involved in binding for both chemicals (Fig. 4b, c).
Discussion
Laboratory investigations of neonates exposed to HIV 
drugs suggest that these compounds may alter adrenal 
steroidogenesis [13, 14]. However, so far, these drugs had 
not been tested for their possible effect on adrenal ste-
roidogenesis. In this study, we show that the antiretro-
viral drug efavirenz inhibits the steroidogenic enzyme 
CYP21A2 at therapeutic concentrations in human adre-
nal NCI-H295R cells and in direct kinetic protein interac-
tion assays. Our bioinformatic studies suggest that efavi-
renz is a direct competitor to substrates of the enzyme. By 
contrast, no inhibitory effect on CYP21A2 activity was 
found for zidovudine, emtricitabine, and tenofovir.
Medications in use for HIV treatment fall into differ-
ent categories concerning drug safety (https://aidsinfo.
nih.gov/guidelines). Tested drugs suspected to inhibit 
steroidogenesis are listed in the category characterized by 
limited experience in pregnancy and with incomplete 
data on teratogenicity, toxicity, and drug interactions. In 
the literature, efavirenz has been linked to congenital 
anomalies in monkeys and humans in some studies 
(https://aidsinfo.nih.gov/guidelines [30, 31]), but these 
adverse effects were not confirmed in other studies [32, 
33]. Currently, no restrictions apply to the use of efavi-
renz during pregnancy, neither in British nor US HIV 
treatment guidelines (https://www.bhiva.org/pregnancy-
guidelines and https://aidsinfo.nih.gov/guidelines). Fetal 
exposure to tenofovir was shown to lower bone mineral 
content in infants compared to controls [34]. By contrast, 
no congenital anomalies or adverse effects have been re-
ported with the HIV drug emtricitabine [33, 35, 36].
Concerning interactions of HIV drugs with cyto-
chrome P450 enzymes, nothing was known for steroido-
genic P450 so far. However, ritonavir has been reported 
to inhibit drug-metabolizing CYP2D6 and CYP3A4 en-
zymes [37, 38], while enzyme induction of ritonavir/lopi-
navir on CYP1A2, CYP2C9, and CYP2C19 activities has 
been observed [39]. These drugs have not been tested for 
their effect on CYP21A2 in this study but are currently 
being tested in cell experiments with preliminary results 
showing a marked inhibitory effect of lopinavir but not 
rotinavir on CYP21A2 and a smaller effect on CYP17A1.
Overall, these results suggest that HIV drugs should be 
carefully tested for their possible effect on P450, including 
steroidogenic P450 enzymes, as this may have clinical im-
plications. Mild inhibition of adrenal steroid biosynthesis 
may not have consequences in healthy individuals, but it 
can result in the inability to sustain stressful situations in 
patients with severe disease when there is a high demand 
for stress hormones within minutes. In addition, long-
term, low-grade inhibition of CYP21A2 or other steroid 
enzyme activities may lead to an imbalance between ad-
renal corticosteroids and androgens with all its conse-




































Fig. 3. Effect of HIV drugs on CYP21A2 activity using human re-
combinant CYP21A2 protein produced in bacteria. Protein was 
produced as published. CYP21A2 activity was tested with 5 µM 
17-hydroxyprogesterone (17OHP) as substrate and HIV drugs at 
the following concentrations: emtricitabine (FTC) 50 µM, efavi-
renz (EFV) 50 µM, zidovudine (AZV) 50 µM, and tenofovir (TDF) 
5 µM. Steroids were extracted and analyzed by RP-HPLC (see 
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to mild CYP21A2 deficiency. Such an effect may also re-
sult from medications interfering with steroid enzyme ac-
tivities, as shown for antiepileptic drugs, which can cause 
an increase in androgen production and a polycystic ova-
ry syndrome phenotype [40, 41].
The premature baby described in our case report 
showed positive newborn screening for transient eleva-
tion in plasma 17OHP and increased urinary excretion 
of androgens, estrogens, and progesterones after treat-
ment with HIV drugs during fetal life (tenofovir, efavi-
renz, and emtricitabine) and postnatally (zidovudine). 
While elevated plasma 17OHP during neonatal screen-
ing motivated us to investigate the effect of the HIV 
drugs in question on CYP21A2 activity, elevated urinary 
progesterone excretion may not be explained by 
 CYP21A2 inhibition but rather by CYP17A1 deficiency. 
On the other hand, CYP17A1 deficiency decreases an-





















































































Fig. 4. Structure analysis of the interaction 
between the HIV drug efavirenz and the 
CYP21A2 enzyme. a Efavirenz docked into 
the protein structure of CYP21A2. Proges-
terone (b) versus efavirenz (c) binding pos-
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findings in our case with spontaneous resolution may or 
may not have been due to an adverse drug effect (of efa-
virenz). However, our in vitro and in silico studies show 
that such an effect is clearly seen for efavirenz. Its impact 
should be further explored in larger clinical studies. It is 
therefore important to bring the possible inhibitory ef-
fect of HIV drugs on adrenal steroidogenesis to the at-
tention of the HIV community, as it may have clinical 
implications beyond the neonatal age.
Conclusion
The HIV drug efavirenz inhibits CYP21A2 activity 
in human adrenal NCI-H295R cells at therapeutic con-
centrations apparently by a competitive mechanism. 
This effect has been suspected by laboratory abnormal-
ities found in few newborns treated with HIV drugs. 
Whether this effect is of clinical relevance to the adrenal 
function in health and disease remains to be seen in 
larger clinical studies investigating children and adults 
during HIV drug treatment. So far, we suggest to list 
some HIV drugs (such as efavirenz) as medications that 
may cause a positive neonatal screening test for elevated 
17OHP.
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